Science
Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19 – EurekAlert
This randomized clinical trial compares the effects of three doses of bamlanivimab monotherapy (700 vs 2,800 vs 7,000 mg) vs combination bamlanivimab and etesevimab…
What The Study Did: This randomized clinical trial compares the effects of three doses of bamlanivimab monotherapy (700 vs 2,800 vs 7,000 mg) vs combination bamlanivimab and etesevimab vs placebo on change in day 11 severe acute respiratory syndrome coronavirus 2 viral load in patients with mild to moderate COVID-19.
Authors: Daniel M. Skovronsky, M.D., Ph.D., of Eli Lilly and Company in Indianapolis, is the corresponding author.
To access the embargoed study: Visit our For The Media website at…
-
General22 hours agoThousands of US flights delayed as shutdown bites
-
General21 hours agoRBA governor Bullock says a severe market downturn would raise financial stability concerns
-
Noosa News23 hours agoWhy Cam Green staying at No.3 could help get the best out of Steve Smith during the 2025/26 Ashes
-
Noosa News22 hours agoTeachers asked to vote on state’s ‘best and final’ offer